Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RARE Ultragenyx Pharmaceutical Inc

休市中 05-03 16:00:00 EDT

42.75

-0.45

-1.04%

盘后42.75

+0.000.00%

17:20 EDT

最高46.01	最低42.68	成交量114.30万
今开44.88	昨收43.20	日振幅7.71%
总市值35.54亿	流通市值31.19亿	总股本8,313万
成交额5,040万	换手率1.57%	流通股本7,297万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"RARE","market":"US","secType":"STK","nameCN":"Ultragenyx Pharmaceutical Inc","latestPrice":42.75,"timestamp":1714766400000,"preClose":43.2,"halted":0,"volume":1143019,"hourTrading":{"tag":"盘后","latestPrice":42.75,"preClose":42.75,"latestTime":"17:20 EDT","volume":17155,"amount":733386.7704,"timestamp":1714771255729},"delay":0,"floatShares":72969334,"shares":83133341,"eps":-8.248669,"marketStatus":"休市中","marketStatusCode":7,"change":-0.45,"latestTime":"05-03 16:00:00 EDT","open":44.88,"high":46.005,"low":42.675,"amount":50402794.42780001,"amplitude":0.077083,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.248669,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714982400000},"adr":0,"listingDate":1391144400000,"adjPreClose":43.2,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":44,"preClose":43.2,"latestTime":"09:29 EDT","volume":730,"amount":30254.382800000003,"timestamp":1714742969025},"postHourTrading":{"tag":"盘后","latestPrice":42.75,"preClose":42.75,"latestTime":"17:20 EDT","volume":17155,"amount":733386.7704,"timestamp":1714771255729},"volumeRatio":1.3586142317968595},"requestUrl":"/m/hq/s/RARE","defaultTab":"news","newsList":[{"id":"2432391765","title":"Ultragenyx Pharmaceutical Inc   预计每股亏损1.73美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432391765","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432391765?lang=zh_cn&edition=full","pubTime":"2024-05-01 05:32","pubTimestamp":1714512730,"startTime":"0","endTime":"0","summary":"   * Ultragenyx Pharmaceutical Inc    将于5月2日公布截至2001年1月1日的业绩报告，预计该公司的季度收入将有所增长。* 根据LSEG的数据，17位分析师的平均预期显示，这家总部位于加利福尼亚州诺瓦托的公司的营收将从去年同期的1.005亿美元增至1.1609亿美元，增幅为15.4%。* LSEG 分析师对 Ultragenyx Pharmaceutical Inc 的平均预期是每股亏损 1.73 美元。* 华尔街对 Ultragenyx Pharmaceutical Inc 的 12 个月目标价中位数为 81.50 美元，高于其上次收盘价 44.02 美元。4月30日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429945013","title":"Ultragenyx Pharmaceutical(RARE.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价77.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2429945013","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429945013?lang=zh_cn&edition=full","pubTime":"2024-04-22 17:55","pubTimestamp":1713779754,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical(RARE.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价77.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221755578b45aad9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221755578b45aad9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428532722","title":"Ultragenyx Pharmaceutical Inc.盘中异动 下午盘快速上涨5.11%报44.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428532722","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428532722?lang=zh_cn&edition=full","pubTime":"2024-04-18 02:46","pubTimestamp":1713379584,"startTime":"0","endTime":"0","summary":"北京时间2024年04月18日02时46分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价急速上涨5.11%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为0.79%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。该信息摘要如下：Wedbush：重申Ultragenyx Pharmaceutical评级，由中性调整至中性评级, 目标价48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180246247a538279&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180246247a538279&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427228868","title":"罕见病巨头Ultragenyx(RARE.US)反义寡核苷酸疗法挺进3期临床 剑指天使综合征","url":"https://stock-news.laohu8.com/highlight/detail?id=2427228868","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427228868?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:10","pubTimestamp":1713273046,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Ultragenyx Pharmaceutical宣布其用于治疗天使综合征的在研疗法GTX-102在1/2期临床试验中获得的最新数据。据介绍，天使综合征是一种由UBE3A基因缺失或突变所造成的神经系统发育障碍疾病，主要疾病特征包括发育迟缓、智力残疾、言语及平衡障碍。2019年，Ultragenyx和GeneTx达成合作，共同开展针对这一疾病的反义寡核苷酸疗法GTX-102的研究。2022年，Ultragenyx宣布完成对GeneTx的收购，预付款数额为7500万美元，GeneTx还有资格获得额外的里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103563.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427013650","title":"BUZZ-Ultragenyx 因旧有副作用在试验中再次出现而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2427013650","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427013650?lang=zh_cn&edition=full","pubTime":"2024-04-15 22:09","pubTimestamp":1713190187,"startTime":"0","endTime":"0","summary":" ** 不过，券商补充说，FDA 和其他监管机构没有提出任何问题或要求采取额外行动，这令券商感到鼓舞。** 20家券商中有18家将该股评为 \"买入 \"或更高评级，2家为 \"持有\"；他们的PT中值为82美元** 如果算上本交易日的损失，该股本年累计跌幅约为 8","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427000685","title":"Ultragenyx Pharmaceutical Inc.盘中异动 早盘大幅下跌7.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427000685","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427000685?lang=zh_cn&edition=full","pubTime":"2024-04-15 21:31","pubTimestamp":1713187910,"startTime":"0","endTime":"0","summary":"北京时间2024年04月15日21时31分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价快速下挫7.66%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为0.77%。其相关个股中，Soligenix, Inc.、Organovo Holdings, Inc.、Longeveron Inc.涨幅较大，Allarity Therapeutics, Inc.、Soligenix, Inc.、Longeveron Inc.较为活跃，换手率分别为591.11%、347.01%、254.45%，振幅较大的相关个股有Organovo Holdings, Inc.、Soligenix, Inc.、Cassava Sciences Inc C/Wts 15/11/2024，振幅分别为28.71%、24.09%、19.37%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404152131508b263f79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404152131508b263f79&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427737498","title":"Ultragenyx Pharmaceutical Inc.盘中异动 大幅下挫5.13%报48.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427737498","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427737498?lang=zh_cn&edition=full","pubTime":"2024-04-13 00:19","pubTimestamp":1712938770,"startTime":"0","endTime":"0","summary":"北京时间2024年04月13日00时19分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价急速跳水5.13%。截至发稿，该股报48.10美元/股，成交量18.8758万股，换手率0.23%，振幅4.76%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为1.14%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404130019317a527a28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404130019317a527a28&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425159827","title":"Ultragenyx Pharmaceutical Inc.盘中异动 急速拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425159827","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425159827?lang=zh_cn&edition=full","pubTime":"2024-04-06 00:00","pubTimestamp":1712332808,"startTime":"0","endTime":"0","summary":"北京时间2024年04月06日00时00分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价大幅拉升5.08%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为1.09%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404060000087a511523&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404060000087a511523&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424818315","title":"Ultragenyx Pharmaceutical Inc.盘中异动 大幅拉升5.01%报49.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2424818315","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424818315?lang=zh_cn&edition=full","pubTime":"2024-04-04 22:41","pubTimestamp":1712241708,"startTime":"0","endTime":"0","summary":"北京时间2024年04月04日22时41分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价急速拉升5.01%。截至发稿，该股报49.44美元/股，成交量12.7797万股，换手率0.16%，振幅4.60%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.10%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040422414887e7e0ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040422414887e7e0ac&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417486874","title":"Ultragenyx Pharmaceutical Inc.盘中异动 早盘快速下跌5.08%报50.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417486874","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417486874?lang=zh_cn&edition=full","pubTime":"2024-03-05 23:08","pubTimestamp":1709651285,"startTime":"0","endTime":"0","summary":"北京时间2024年03月05日23时08分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价快速下挫5.08%。截至发稿，该股报50.60美元/股，成交量9.002万股，换手率0.11%，振幅4.87%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为1.38%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240305230806861db6f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240305230806861db6f1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416962207","title":"Ultragenyx Pharmaceutical Inc.盘中异动 股价大涨5.01%报54.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2416962207","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416962207?lang=zh_cn&edition=full","pubTime":"2024-03-02 02:15","pubTimestamp":1709316934,"startTime":"0","endTime":"0","summary":"北京时间2024年03月02日02时15分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价急速拉升5.01%。截至发稿，该股报54.31美元/股，成交量23.1266万股，换手率0.28%，振幅4.37%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为2.61%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403020215347916685f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403020215347916685f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414849832","title":"美国研究综述-Agiliti、多米诺比萨、Krystal 生物技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2414849832","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414849832?lang=zh_cn&edition=full","pubTime":"2024-02-27 15:31","pubTimestamp":1709019083,"startTime":"0","endTime":"0","summary":"    路透社2月27日 - 华尔街证券分析师周二调整了对 Agiliti、多米诺比萨和 Krystal Biotech 等几家美国上市公司的评级和目标价。公司要闻             * Agiliti公司  ：杰富瑞将其评级从 \"买入 \"下调至 \"持有  * 多米诺比萨  ：杰富瑞将目标价从400美元上调至455美元              * Krystal Biotech Inc   ：Evercore ISI将其股票从战术跑赢大盘名单中除名  以下是路透社周二报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413279854","title":"Ultragenyx Pharmaceutical Inc2023财年实现净利润-6.07亿美元，同比增加14.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413279854","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413279854?lang=zh_cn&edition=full","pubTime":"2024-02-23 07:18","pubTimestamp":1708643938,"startTime":"0","endTime":"0","summary":"12月31日，Ultragenyx Pharmaceutical Inc公布财报，公告显示公司2023财年净利润为-6.07亿美元，同比增加14.14%；其中营业收入为4.34亿美元，同比增加19.56%，每股基本收益为-8.25美元。机构评级：截至2023年12月31日，当前有20家机构对Ultragenyx Pharmaceutical Inc目标价做出预测，其中目标均价为89.65美元，其中最低目标价为48.00美元，最高目标价为140.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022307190881aa54cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022307190881aa54cd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2412930596","title":"Ultragenyx Pharmaceutical Inc盘中异动 快速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2412930596","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2412930596?lang=zh_cn&edition=full","pubTime":"2024-02-17 01:04","pubTimestamp":1708103096,"startTime":"0","endTime":"0","summary":"北京时间2024年02月17日01时04分，Ultragenyx Pharmaceutical Inc股票出现波动，股价快速上涨5.10%。Ultragenyx Pharmaceutical Inc股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Ys Biopharma Co Ltd C/Wts 15/03/2028 、Seastar Medical Holding Corp C/Wts 28/10/2027 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Kintara Therapeutics Inc、Novabay Pharmaceuticals Inc、Tc Biopharm  Plc较为活跃，换手率分别为181.75%、23.37%、22.82%，振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为62.99%、61.50%、57.89%。Ultragenyx Pharmaceutical Inc公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402170104577a440427&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402170104577a440427&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411577246","title":"Ultragenyx Pharmaceutical Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2411577246","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411577246?lang=zh_cn&edition=full","pubTime":"2024-02-16 06:50","pubTimestamp":1708037453,"startTime":"0","endTime":"0","summary":"   * Ultragenyx Pharmaceutical Inc   报告了截至12月底的季度调整后每股亏损1.52美元，高于去年同期的每股亏损2.16美元。华尔街预期为每股亏损 2.45 美元至-71 美分。* 营收同比增长 23.3%，达到 1.2739 亿美元；分析师预期为 1.1938 亿美元。* Ultragenyx Pharmaceutical Inc公布的本季度每股收益为亏损1.52美元。* 该公司一季度亏损 1.2319 亿美元。* Ultragenyx Pharmaceutical Inc 本季度股价下跌了 4.5%。华尔街对 Ultragenyx Pharmaceutical Inc 的 12 个月目标价中位数为 82.00 美元。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411390896","title":"Ultragenyx Pharmaceutical Inc   预计每股亏损1.62美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2411390896","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411390896?lang=zh_cn&edition=full","pubTime":"2024-02-14 05:39","pubTimestamp":1707860379,"startTime":"0","endTime":"0","summary":"   * Ultragenyx Pharmaceutical Inc    将于2月15日公布截至2023年12月31日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，14位分析师的平均预期显示，这家总部位于加利福尼亚州诺瓦托的公司的营收将从去年同期的1.0335亿美元增至1.1938亿美元，增幅为15.5%。* LSEG 分析师对 Ultragenyx Pharmaceutical Inc 的平均预期是每股亏损 1.62 美元。* 华尔街对 Ultragenyx Pharmaceutical Inc 的 12 个月目标价中位数为 82.00 美元，高于其上次收盘价 46.74 美元。2月13日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411836038","title":"Ultragenyx Pharmaceutical Inc盘中异动 大幅下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2411836038","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411836038?lang=zh_cn&edition=full","pubTime":"2024-02-14 01:45","pubTimestamp":1707846308,"startTime":"0","endTime":"0","summary":"北京时间2024年02月14日01时45分，Ultragenyx Pharmaceutical Inc股票出现异动，股价急速跳水5.01%。Ultragenyx Pharmaceutical Inc股票所在的生物技术行业中，整体跌幅为0.65%。其相关个股中，Pasithea Therapeutics Corp C/Wts 12/08/2026 、Tc Biopharm  Plc C/Wts 10/02/2028 、Zura Bio Limited C/Wts 20/03/2028 涨幅较大，Biodexa Pharmaceuticals Plc、Revelation Biosciences Inc、Adial Pharmaceuticals Inc较为活跃，换手率分别为422.74%、209.25%、128.23%，振幅较大的相关个股有Cingulate Inc C/Wts 10/12/2026 、Renovaro Biosciences Inc、Calidi Biotherapeutics Inc，振幅分别为53.85%、51.26%、50.00%。Ultragenyx Pharmaceutical Inc公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240214014508861d51b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240214014508861d51b0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2404048328","title":"美国研究综述-Burlington Stores、Carrols Restaurant Group、Mastec","url":"https://stock-news.laohu8.com/highlight/detail?id=2404048328","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2404048328?lang=zh_cn&edition=full","pubTime":"2024-01-17 15:02","pubTimestamp":1705474948,"startTime":"0","endTime":"0","summary":"    路透1月17日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括伯灵顿百货公司、Carrols Restaurant Group 和 Mastec。要点             * Ambrx Biopharma Cayman Inc   ：贝雅将其评级下调至中性             * Burlington Stores Inc   ：Piper Sandler将其评级从中性上调至增持              * Carrols Restaurant Group Inc   ：Stephens将其评级从 \"增持 \"下调至 \"等权重\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2393962112","title":"Ultragenyx Pharmaceutical Inc盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2393962112","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2393962112?lang=zh_cn&edition=full","pubTime":"2023-12-21 04:54","pubTimestamp":1703105670,"startTime":"0","endTime":"0","summary":"北京时间2023年12月21日04时54分，Ultragenyx Pharmaceutical Inc股票出现异动，股价急速下挫5.04%。Ultragenyx Pharmaceutical Inc股票所在的生物技术行业中，整体跌幅为1.59%。其相关个股中，Artelo Biosciences Inc C/Wts 20/06/2024 、Pasithea Therapeutics Corp C/Wts 12/08/2026 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大，Panbela Therapeutics Inc、Tracon Pharmaceuticals Inc、Bluebird Bio Inc较为活跃，换手率分别为196.61%、123.87%、109.28%，振幅较大的相关个股有Artelo Biosciences Inc C/Wts 20/06/2024 、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Pasithea Therapeutics Corp C/Wts 12/08/2026 ，振幅分别为396.32%、134.55%、131.71%。Ultragenyx Pharmaceutical Inc公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231221045430861c5e63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231221045430861c5e63&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2392181957","title":"Ultragenyx Pharmaceutical Inc盘中异动 临近收盘股价大涨5.08%报47.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2392181957","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2392181957?lang=zh_cn&edition=full","pubTime":"2023-12-20 04:34","pubTimestamp":1703018099,"startTime":"0","endTime":"0","summary":"北京时间2023年12月20日04时34分，Ultragenyx Pharmaceutical Inc股票出现波动，股价大幅拉升5.08%。截至发稿，该股报47.98美元/股，成交量34.8846万股，换手率0.42%，振幅4.98%。Ultragenyx Pharmaceutical Inc股票所在的生物技术行业中，整体涨幅为0.08%。Ultragenyx Pharmaceutical Inc公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122004345983a52300&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122004345983a52300&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ultragenyx.com","stockEarnings":[{"period":"1week","weight":-0.0337},{"period":"1month","weight":-0.092},{"period":"3month","weight":-0.0063},{"period":"6month","weight":0.101},{"period":"1year","weight":-0.0668},{"period":"ytd","weight":-0.106}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ultragenyx Pharmaceutical Inc.于2010年4月22日成立，是一家处于发展阶段的生物科技企业，公司随后于2011年6月在特拉华州重新注册成立。公司专注于新型产品的鉴定、收购、开发与商业化，该产品主要用于治疗罕见和极罕见的疾病，产品最初目标是用于治疗严重的，令人衰弱的代谢基因类疾病。公司目前用于治疗遗传性包涵体肌病患者的缓释唾液酸正处于临床试验第二阶段，该疾病是一种渐进式的肌肉萎缩疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.014003},{"month":2,"riseRate":0.636364,"avgChangeRate":0.079614},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.047001},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.001553},{"month":5,"riseRate":0.545455,"avgChangeRate":0.049303},{"month":6,"riseRate":0.7,"avgChangeRate":0.068734},{"month":7,"riseRate":0.4,"avgChangeRate":0.015854},{"month":8,"riseRate":0.5,"avgChangeRate":0.006387},{"month":9,"riseRate":0.2,"avgChangeRate":-0.064028},{"month":10,"riseRate":0.2,"avgChangeRate":-0.074469},{"month":11,"riseRate":0.5,"avgChangeRate":0.050565},{"month":12,"riseRate":0.7,"avgChangeRate":0.064436}],"exchange":"NASDAQ","name":"Ultragenyx Pharmaceutical Inc","nameEN":"Ultragenyx Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ultragenyx Pharmaceutical Inc,RARE,Ultragenyx Pharmaceutical Inc股票,Ultragenyx Pharmaceutical Inc股票老虎,Ultragenyx Pharmaceutical Inc股票老虎国际,Ultragenyx Pharmaceutical Inc行情,Ultragenyx Pharmaceutical Inc股票行情,Ultragenyx Pharmaceutical Inc股价,Ultragenyx Pharmaceutical Inc股市,Ultragenyx Pharmaceutical Inc股票价格,Ultragenyx Pharmaceutical Inc股票交易,Ultragenyx Pharmaceutical Inc股票购买,Ultragenyx Pharmaceutical Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况